Urology company Corinth MedTech stated on Friday that it has raised USD12m under its equity financing led by ShangBay Capital LLC,Aethan Capital Inc as well as existing investors.
Proceeds from the financing will be used by Corinth MedTech to launch the commercialisation of the Veloxion System, which received US Food and Drug Administration (FDA) 510(k) clearance, for the treatment of BPH (Benign Prostatic Hyperplasia) and TURBT (Transurethral Resection of Bladder Tumor).
Concurrent with the financing, William Dai, founding partner of ShangBay Capital, will join the Corinth MedTech's board of directors.
Additionally, ShangBay Capital is Corinth MedTech's new investor, said president and CEO Csaba Truckai.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT